Aquatic Capital Management’s Travere Therapeutics TVTX Stock Holding History

Aquatic Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.96M	Buy	157,710 +122,318	+346%	+$5.42M	0.31%	66
2026 Q1	$1.05M	Sell	35,392 -23,727	-40%	-$709K	0.03%	548
2025 Q4	$2.26M	Buy	+59,119	New	+$1.92M	0.06%	355
2025 Q2	–	Sell	-64,762	Closed	-$1.16M	–	1553
2025 Q1	$1.16M	Buy	64,762 +32,795	+103%	+$666K	0.03%	564
2024 Q4	$557K	Buy	+31,967	New	+$565K	0.02%	690
2024 Q3	–	Sell	-3,100	Closed	-$25.5K	–	1557
2024 Q2	$25.5K	Buy	+3,100	New	+$20.9K	﹤0.01%	1080
2023 Q3	–	Sell	-2,600	Closed	-$40K	–	1672
2023 Q2	$40K	Sell	2,600 -2,900	-53%	-$52.8K	﹤0.01%	1034
2023 Q1	$124K	Buy	+5,500	New	+$117K	0.01%	701

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's TVTX Position: Q2 2026 in Review

Aquatic Capital Management increased its Travere Therapeutics (TVTX) stake by 346% in Q2 2026, buying an estimated $5.42M and bringing the position to 157,710 shares worth $8.96M. The position accounts for 0.31% of the portfolio, ranked #66.

Aquatic Capital Management first reported a position in TVTX in Q1 2023 and has held it in 8 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Aquatic Capital Management held 157,710 shares of Travere Therapeutics worth $8.96M as of Q2 2026.
Aquatic Capital Management bought 122,318 Travere Therapeutics shares in Q2 2026, an estimated $5.42M.
Travere Therapeutics made up 0.31% of Aquatic Capital Management's portfolio in Q2 2026, its #66 holding.
Aquatic Capital Management first reported a position in Travere Therapeutics in Q1 2023 and has held it in 8 quarters since.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.